Figures & data
Table 1 Sociodemographic and Clinical Characteristics of the Study Participants
Table 2 Measures of Diabetes Clinical Outcomes
Table 3 Total Daily Dose Variation (Sub-Analysis for Both Basal Insulin Types: Glargine U300 and Degludec U100)
Table 4 The Marginal Response of Diabetic Ketoacidosis (DKA)
Table 5 Frequency of Diabetic Ketoacidosis (DKA) Before and After Using Insulin Degludec U100 or Glargine U300; Sub-Analysis